An open-label randomized controlled trial of leflunomide in patients with acute SARS-CoV-2 omicron variant infection

OBJECTIVE: To evaluate the efficacy and safety of leflunomide for the treatment of acute, symptomatic COVID-19. METHODS: A single-center, open-label, randomized controlled trial was performed during an outbreak of SARS-CoV-2 Omicron variant in December 2022. Symptomatic patients within 5 days of COV...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Zhou, Wan, Zhihui, Wang, Yixuan, Zha, Shiqian, Zhang, Jingyi, Chen, Hao, Hu, Ke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392126/
https://www.ncbi.nlm.nih.gov/pubmed/37534317
http://dx.doi.org/10.3389/fmed.2023.1218102

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10392126/
https://www.ncbi.nlm.nih.gov/pubmed/37534317
http://dx.doi.org/10.3389/fmed.2023.1218102

Ejemplares similares